Breaking the Cycle of Heterosexual Transmission

Excerpted from Px Wire, this is a novel look at how to use today’s tools to break the cycle of heterosexual transmission that was so clearly defined in a major AIDS 2016 presentation.

New Px Wire: Where did Durban leave HIV prevention?

The International AIDS Conference closed exactly a month ago today. While it lacked the pageantry of last night’s Olympics closing ceremony—which included a prime minister dressed as a video game character—the Durban wrap-up was a reminder of how important the meeting can be in framing global issues and priorities. AVAC’s new issue of Px Wire offers a look at how the Durban wrap-up catapults us into the future.

Click here to download the new issue.

And don’t miss our centerspread graphic:

  • A scorecard for the conference—how did it deliver?
  • A novel look at how to use today’s tools to break the cycle of heterosexual transmission that was so clearly defined in a major Durban presentation.

ARV-Based Prevention Pipeline

The pipeline of ARV-based prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable ARVs. Not pictured are a range of multipurpose technologies in development that aim to reduce women’s risk of HIV and STIs, and provide effective contraception.

Evidence for HIV Prevention Options

What’s the big picture of ARV-based prevention trial results? This graphic shows the levels of efficacy from each major trial (the circles) with the confidence intervals around the finding (the bars at either side). Not sure what a confidence interval is? See our one-page Advocates’ Guide to Statistical Terms.

The Vagina Dialogues – Day 3 at AIDS 2016 

We head into day three of the Durban Diaries a little deafer than we were before from the unceasing din of the Global Village—a beat that breaks down into equal parts information, activism and celebration of all the shapes and sizes and colors of our lives. Between the pink-peacock-feather-clad dancers in the condom area and the music of Ugandan singer Moses Supercharger on the Global Village mainstage, it’s a feast for all five senses, and a reminder of the beauty of the bodies we live in every day.

Over in the main conference building, the beauty of those bodies was in and out of focus today in a series of sessions focused on women, HIV risk and HIV prevention. At its best, the dialogue was led by and for women and centered on rights, realities and engaged discussion on the whole body, from head to toe and heart to mind. In some fascinating sessions, the vagina seized center stage and all but lost the head and heart that go with it. Today, in our update, we’ll try to put the pieces together and so, of course, the theme is: The Vagina Dialogues.

The morning’s plenary featured a number of powerful women who reminded delegates of the role of gender in the global response to the epidemic. Eminent Kenyan scientist and advocate Elizabeth Bukusi, of KEMRI, reminded the audience that, “HIV operates in a gendered world and it thrives because of that.”

What exactly is going on in that gendered world? Some insights came from a special session, New Evidence: Why Do Young Women in Africa Have High Rates of HIV Infection?. It started out with a presentation on the “direction” of transmission in a South African community—in other words, who is passing on the virus to whom, by gender and age-bracket. By sequencing viruses and grouping them according to their genetic relatedness, researchers established that the majority of young women [16–24 years old] are acquiring HIV from significantly older men—an average of 11 years older, in fact. The age disparity between male and female partners decreases as young women age. But many of them are getting HIV from older male partners so that by the time they are 24, they are also in a position to transmit HIV to their male partners, setting up a cycle that looks like this.

The session also presented data drawn from women who participated in the CAPRISA 004 trial of a 1% microbicide gel. This investigation explored the presence of specific vaginal bacteria (the flora that live in all women’s vaginas) and how it might increase HIV risk and affect the absorption of the tenofovir gel. The good news is that there is no evidence these findings apply to the use of oral PrEP.

This session provided great food for thought including this comment—voiced in the follow-on session on women’s rights and health: “We heard all about vaginas. But vaginas are attached to people…” The challenge will be to put these important scientific findings into practice in ways that explore young women’s practices in relation to their vaginal health, and their whole bodies—all while treating and PrEPing as needed.

Speaking of vaginas, another study presented today focused on new analyses of data from the ASPIRE dapivirine vaginal ring study. While initial data were presented at CROI, new analyses showed that individuals with high levels of adherence achieved extremely high levels of protection.

Back in the Global Village, no surprise here, women’s bodies and lives were fully present in all sorts of sessions; a vibrant discussion in the Women’s Networking Zone ensued from a project documenting the experiences and perspectives of women living with HIV and undergoing treatment. Women at the session, who were primarily from sub-Saharan Africa, found the findings from this project personally resonant and were eager to obtain the full report as an advocacy tool. Download the four-page summary here.

Wednesday at the Research Literacy Networking Zone

In addition to having a Help Desk (have a question about prevention research or looking for a resource—stop in!) and a comfortable space to rest your feet, come check out all the programming in the RLNZ (Global Village, Booth 606). See Wednesday’s schedule below:

  • 11:00 – 12:30 – Safer Conception for HIV-affected Individuals and Couples: Synopses of Findings (HIVE)
  • 12:45 – 13:45 – Addressing Known Causes of Poor Participation by Black MSM in HIV Prevention and Treatment Research (APEB, PxROAR)
  • 14:00 – 15:00 – Advancing PrEP Advocacy Opportunities and Challenges in Settings Where it Has Been Approved and Where it Has Not (IRMA)
  • 15:30 – 16:30 – Hope vs. Hype in Reporting HIV Cure Research (AVAC, TAG, UNC)
  • 17:30 – 18:30 – Ask the Researcher: Preventive HIV Vaccine Research (HVTN)

A Few Sessions We’ve Starred

See below for a highly selective list of sessions for all the data geeks out there! Check them out in-person or find them on the webcast archive the following day.

  • 8:45 – 10:55 – What is our goal?, Session Room 1, Wednesday’s plenary features AVAC team member Micheal Ighodaro speaking on the role of young people leading in the response
  • 11:00 – 12:30 – Making PrEP Real for Those Who Need It Most: Optimization Strategies, Session Room 1, Data from IPERGAY and HPTN 073 and Partners Demo studies and SEARCH test and treat study in Uganda and Kenya
  • 13:00 – 14:00 – Accelerating the Decline of the Burden and Incidence of HIV in Sub-Saharan Africa Special Session, Session Room 1
  • 13:00 – 14:00 – Circumcision: Where to, How to, Who to?, Session Room 5, Oral poster discussion on VMMC uptake, barriers, new devices and more
  • 13:00 – 14:00 – Prevention for Women: The Need for Multidisciplinary Approaches, Session Room 8, Oral-poster session including additional qualitative data from FACTS 001, preferred PrEP formulation in ASPIRE sub-study, vaginal bacteria and its relation to increased risk of HIV, and more

Follow along in real-time on Twitter, and look for the next update in your inbox tomorrow!

Biomedical Prevention in 2016 – At a Glance

A snapshot of prevention strategies underway or under development from 2015-2020. Excerpted from AVAC Report 2016: Big Data, Real People.

Dapivirine Vaginal Ring Results

An overview dapivirine ring results and the product pipeline. Excerpted from AVAC Report 2016: Big Data, Real People.

HIV Prevention Research Status Report

A survey of prevention strategies and the status of their safety and efficacy. Excerpted from AVAC Report 2016: Big Data, Real People.

New! AVAC Report 2016 Big Data, Real People: The annual state of prevention advocacy

If you’re packing for Durban, we hope you’ll pause right now and add to your bag AVAC’s annual state of the field, Big Data Real People. The full PDF, Executive Summary and graphics are available here.

As always, AVAC Report is our annual advocacy analysis, with an agenda that spans the next 12 months—and beyond. We’ve designed it be a clear, succinct, actionable statement of the strengths and weakness of HIV prevention data today—and we hope you’ll join us in amplifying these messages at next week’s gathering.

Even if you’re not heading to Durban, we hope that this year’s Report will top your packing list for the journey through the next 12 months of advocacy and action.

In the Report, we argue that the state of HIV prevention data collection in 2016 is poor. One part of the solution lies in the adoption of “HIV Prevention Data Dashboards”. This tracking tool could bring the same specificity and accountability to non-ART prevention services that the “treatment cascade” of diagnosis, initiation, retention and virologic suppression does for antiretrovirals for people living with HIV.

The world cannot even pretend that ending AIDS is possible without action on non-ART prevention. We need to roll out what we have, continue R&D on what we still need, as well as scale up ART for all people living with HIV. That’s what the new UNAIDS Prevention Gap report says. That’s what AVAC has said for years. That’s what we hope you’ll say in Durban and over the coming year.

Here’s the Report, a roadmap for the coming year. Please read it, join us on the journey, let us know what you think!

Press Release

Data gaps hinder global efforts to reduce HIV infections, AVAC report warns; improved data collection and reporting needed to meet looming global AIDS targets

Contacts

Mitchell Warren, mitchell@avac.org, +1-914-661-1536
Kay Marshall, kay@avac.org, +1-347-249-6375

In a report issued today, AVAC warned that major gaps in global HIV/AIDS data stand in the way of delivering HIV prevention advances to millions of people who need them most. The report identifies several critical weaknesses of today’s HIV prevention data collection and monitoring systems and offers a concrete roadmap for closing these gaps. The report, Big Data, Real People, was issued ahead of next week’s International AIDS Conference in Durban, South Africa (July 18-22), where advocates will demand action to speed HIV prevention research and delivery.

“In an era in which big data are expected to improve essentially every part of our lives, there’s no excuse for HIV prevention data systems to be so uneven, incomplete and inefficient,” said Mitchell Warren, AVAC’s executive director. “To have any chance of ending the epidemic by 2030, we need to be collecting and accounting for every bit of useful information from every person living with or at risk for HIV.”

The need for improved HIV prevention data systems is particularly pressing given the UNAIDS “fast-track” goal to reduce new annual diagnoses to no more than 500,000 by 2020. Earlier this month, UNAIDS reported that the number of new HIV infections has remained near 2 million per year for the past decade.

Report identifies specific HIV data gaps, recommends solutions

AVAC’s report focuses on four critical data gaps that must be addressed to effectively prioritize, target and measure the impact of efforts to develop and deliver HIV prevention advances.

Specifically, today’s HIV prevention data are:

  • Not sufficiently broken down by age, gender, income status, key population status and other vital categories
  • Missing or incomplete for key populations most in need of prevention, including adolescent girls and young women, men who have sex with men, transgender women, and others
  • Not tied to useful HIV prevention metrics and indicators, so that it is impossible to know whether prevention programs are actually averting infections and improving health
  • Not effectively informing the HIV prevention research agenda

To overcome these weaknesses, the report outlines three critical strategies that should be pursued most urgently:

1. Standardize and systemize data collection and reporting for HIV prevention

Understand, measure and report on the risk level of people testing HIV-negative; create and measure linkages to evidence-based prevention for people at substantial risk; and use a standardized “Prevention Data Dashboard” to continually evaluate progress. Such dashboards would consolidate and arrange available data to illuminate critical prevention gaps and help the global community, governments and funders better conceptualize their HIV prevention programming and evaluation. AVAC’s report provides a model dashboard for decision-makers to adopt.

2. Improve use of data for adolescent girls and young women

Ensure that a growing volume of available data can be applied in a meaningful way. As a first step, funders, implementers and governments need to do a better job of defining and segmenting this population; map who is investing in what and where; put adolescent girls and young women in control of core aspects of the data-collection enterprise; and adopt gender-specific indicators tailored to girls and women.

3. Put research on the “fast-track” and countries at the center

Fit biomedical HIV prevention research into comprehensive prevention plans tied to national targets for incidence reduction. Countries and research institutions must invest time and resources in stakeholder engagement; ensure that research priorities are informed by epidemiological and other quality HIV data; and develop national research plans for meeting the prevention needs of specific, affected populations.

The new report and related resources, including downloadable graphics, are available now at www.avac.org/report2016.

###

About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.